The Globe and Mail reports in its Wednesday edition that Eli Lilly said on Tuesday it will buy three vaccine developers in deals worth up to nearly $4-billion (U.S.) in combined value, signalling its push into infectious disease prevention. A Reuters dispatch to The Globe reports that Eli Lilly is acquiring Curevo, LimmaTech Biologics and Vaccine Company. It has been on an acquisition spree, boosted by cash from the booming demand for its obesity drugs. Its deal spending in 2026 has outpaced that in the prior years. The deals mark its renewed move into the infectious disease space, which was largely sidelined in recent years as it focused on expanding its other pipelines. Eli Lilly's Daniel Skovronsky said, "These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences." Citi analyst Geoffrey Meacham said, "We think this is a well-balanced foray into a new area and note each company's lead asset could bring substantial market opportunity and platform validation for future products." He added the focus of each of the vaccine developers highlights viral pathogens linked to long-term neurological and oncology risks, which are in line with Lilly's existing interests.